Knowledge (XXG)

Advisory Committee on the Virological Safety of Blood

Source đź“ť

1340:...and then we have in October of 1991 an 11th meeting of that committee, the Advisory Committee on the Virological Safety of Blood considering recommendations in relation to HCV testing and the results of the first HCV test trials and the possibility of look-back study although no decision then taken.... 1622:
Recommendations to proceed with the introduction of the anti-Hep C testing were made by the relevant UK Committee, the ACVSB, in July and November 1990, subject to the holding of various trials. Ministerial approval was given on 21 January 1991 and a programme of implementation was then commenced for
420:
of 13 May 2019, there were 17 volumes of papers generated by the advisory committee during the course of its operation. The investigation by the Department's internal auditors conducted in April 2000 found that of the 17 volumes, 14 had been destroyed and only volumes 1-3 survived. A court disclosure
520:
Prior to the formation of SaBTO advice was provided at UK Government level by the Committee for the Microbiological Safety of Blood, Tissues and Organs (MSBTO) and its predecessor, the Committee for the Microbiological Safety of Blood and Tissues (MSBT) (1993 -2007). Prior to that we understand that
184:
After the inaugural meeting of 4 April 1989, the advisory committee met a further 13 times, with the fourteenth meeting being held on 29 September 1992. The files and minutes of the committee do not continue beyond February 1993 by which time the ACVSB was considered defunct. Following a memorandum
433:
A significant decision made by the committee in November 1990 was to recommend to Ministers that routine anti-HCV screening of blood be introduced. However, the ACVSB decision was not implemented until September 1991 which came under criticism in the Final Report of the Penrose Inquiry for having
411:
It came to light in 2004 that documentation that fell within the scope of NHS contaminated blood products had gone missing from within the Department of Health and was thought to have been destroyed in the early 1990s. It was claimed by the (then) Minister of State, Lord Warner, that the files in
135:
on the safety of blood with respect to viral infections. The scope of the ACVSB concerned areas of significant policy for the whole of the United Kingdom and operated under the terms of reference: "To advise the Health Departments of the UK on measures to ensure the virological safety of blood,
452:, or deed of undertaking, aimed at ensuring that the claimants would not be able to litigate against the government if they were found to have contracted any further viruses. It was recorded in Hansard in 2007 that a number of these deeds of undertaking from 1989 were inadvertently destroyed. 1401:"Dry heat treatment of 8O°C for 72 hours reduced but did not always eliminate detectable B19 from factor VIII concentrates, consistent with recent observations that current methods of viral inactivation during blood product manufacture are insufficient to entirely eliminate B19 infectivity. 354:
Hepatitis C, screening of non UK plasma in blood products, results of first HCV testing trials, ALT testing, use of plasma from anti-HBc positive donors with a history of jaundice, re-admittance of donors not confirmed HIV antibody positive, HTLV-I BTS study, possible look-back study.
1563:
Penrose ruled that, overall, little could have been done differently by the authorities to prevent the contamination, but that mistakes were made. He criticised a 10-month delay in 1990 by the advisory committee on the virological safety of blood to recommend that screening
727:, 11 (EWCH 2001) ("...and reported back to the two high powered committees on which he sat, the UK Advisory Committee on Virological Safety of Blood ('ACVSB'), and the UK Advisory Committee on Transfusion Transmitted Diseases ('ACTTD')..."). 1324: 136:
whilst maintaining adequate supplies of appropriate quality for both immediate use and for plasma processing." Of particular emphasis to the remit was the testing of blood donors using surrogate markers for Non-A Non-B hepatitis (NANBH) and later on,
412:
question had been identified by the Department of Health as minutes and background papers of the ACVSB spanning May 1989 to February 1992 and that they were "unfortunately destroyed" having not been properly archived. In May 2006, it was recorded in
323:
meeting on Hepatitis C, protocol for HCV Screening and supplementary testing, EC directive on viral safety, EC directive on blood products, hepatitis C: Community transmission, anti-HBc testing of blood donors, hepatitis BsAg confirmatory testing,
143:
The first meeting took place on 4 April 1989 and was chaired by the (then) Deputy Chief Medical Officer (DCMO), Dr E L Harris. From August 1989, Dr J Metters, also DCMO, sat as chair. The advice to be given by the committee extended to
1683:
It is also believed that the committee was responsible for suggesting that those who had been infected with HIV and wanted compensation should sign a waiver agreeing not to sue if they were later found to have contracted other
1592:
The Inquiry has endeavoured to assess why there was a delay of almost 10 months between the decision by the ACVSB on 21 November 1990 to recommend the introduction of screening as soon as practicable and 1 September
1741: 861: 1481: 500: 1517: 1623:
all RTCs. The tests (by now second generation tests, and with a supplementary test available for confirmatory purposes in place) were introduced throughout England and Wales on 1 September 1991.
320: 308:
Hepatitis C testing, counselling of HCV positive donors, anti-HBc testing, reinstatement of donors found to be reactive in previously-used HIV screening tests, HCV in the community.
1666: 416:
that officials became aware of the destruction of the files as early as April 2000, at which point the Department of Health undertook an internal audit. According to a report in
370:, non HCV-tested plasma, EC directive on blood products, ALT testing of blood and plasma, HTLV-I testing of blood donations, non-viral infections of blood transfusions including 718: 435: 422: 461: 1653:
The ACVSB had advised ministers to require victims to sign a waiver agreeing not to pursue the Government over hepatitis infections when applying for compensation.
260:
Human Growth Hormone, EC directive on blood products, HTLV-I screening, Non A Non B hepatitis, report on UKBTS survey of surrogate testing and Chiron screening.
1731: 1234: 1488: 438:
in that ministerial approval had been given on 21 January 1991, yet the second generation tests were not introduced in England and Wales until 1 September 1991
820:
The ACVSB advised the UK government, among other things, on surrogate testing of blood donors for NANB Hepatitis and screening of donors for Hepatitis C.
185:
from NHS Management Executive dated 8 February 1993, the ACVSB was replaced by the committee on the Microbiological Safety of Blood and Tissues (MSBT).
685: 466: 1547: 425:
dated 9 May 2000 also confirms that ACVSB volumes 4-17 of file series "GEB1" were destroyed at various stages between July 1994 and March 1998.
237:
EC directive on blood products, HGH, HTLV-I, Non A Non B hepatitis, action in response to reports of blood/blood product infectivity, effect of
132: 585: 1736: 1697: 1440: 366:
Funding anti-HCV screening, chronology of HCV testing, preliminary analysis of HCV testing, evaluation of in-vitro diagnostics by
833: 385:
Anti-HTLV testing/screening, virus inactivated plasma (VIP), initial screening and alternatives to PCR/RIPA confirmatory tests.
271:
Human Growth Hormone, EC directive on blood products, HTLV-I screening, Non A Non B hepatitis, combined HIV 1 and HIV2 testing.
1636: 173: 521:
advice was provided on a national level by a body called the Advisory Committee on the Virological Safety of Blood (ACVSB).
161: 1461: 544:, 100 (EWHC 2001) ("The Department confirmed to Dr Gunson on 8 March 1989, when it set up the ACVSB..."). 1708:
A number of signed waivers, going back to 1989, were inadvertently destroyed with the files in which they were held.
846:
Surrogate testing of blood donations in relation to Non A Non B hepatitis formed an important part of its business.
471: 445: 939:
Each group met in May 1989: the ACTTD had its second meeting on 19 May and the ACVSB its second meeting on 22 May.
705:
I have also been Chairman of the Advisory Committee of the Virological Society of Blood (ACVSB) since August 1989.
367: 325: 1414: 1576: 807: 554: 128: 1726: 1061:
Below is the agenda for the 4th meeting of the ACVSB, to be held at 1030hrs Monday 6 November 1989...
741:"Note of Meeting of the Advisory Committee on the Virological Safety of Blood held at Hannibal House" 1041: 1009: 919: 776: 740: 620: 1140: 567:
Dr Gunson had recommended to the DHSS that a group should be established and this had been agreed.
980: 891:"Advisory Committee on the Microbiological Safety of Blood and Tissue for Transplantation (MSBT)" 343:
Protocol for hepatitis C screening and supplementary testing, anti-HCV tests on blood donations.
1606:"A & Ors v National Blood Authority & Ors [2001] EWHC QB 446 (26th March, 2001)" 1172: 1108: 137: 1356:"Minutes of the Twelfth Meeting of the Advisory Committee on the Virological Safety of Blood" 434:
been delayed by 10 months. In 2001, the role of the ACVSB was referred to in the judgment of
226:, EC directive on blood products, overview on hepatitis, hepatitis B, Non A Non B hepatitis. 1577:"Final Report: Chapter 31 - The Introduction of Screening of Donated Blood for Hepatitis C" 792:
He explained that the Committee had been set up to give advice to the UK Health Ministers.
604:
The committee produced 17 volumes of documents and the files were closed in February 1993.
476: 165: 157: 153: 1605: 724: 541: 81:
Blood safety, maintaining adequate blood supplies, testing and screening of blood donors
1204: 951: 397: 223: 149: 124: 1294: 652: 293:
Hepatitis C testing, anti-HCV ELISA tests, chimpanzee study of Anti-HCV tested source
1720: 145: 282:
EC directive on blood products, HIV 1 and 2 testing, Hepatitis C, anti HCV testing.
1262: 1076: 294: 169: 1439:
Lord Warner, The Minister of State, Department of Health (27 February 2006).
1355: 890: 246: 211:
Creutzfeldt-Jakob Disease, the EC directive on blood products, HTLV-I testing.
1384: 1548:"Cameron apologises to those infected with hepatitis C and HIV 30 years ago" 1263:"Tenth Meeting of the Advisory Committee on the Virological Safety of Blood" 590: 417: 238: 120: 867:(Report). Infected Blood Inquiry. 19 October 2021. p. 218. WITN0672006 1141:"Seventh Meeting of the Advisory Committee on Virological Safety of Blood" 152:
as well as blood, and the viral agents to be considered by the group were
371: 1696:
Caroline Flint, Minister of State for Public Health (14 May 2007).
1460:
Caroline Flint, Minister of State for Public Health (23 May 2006).
1415:
HIV and Hepatitis C infection from contaminated blood and blood products
997:
The report was given to the third meeting of the ACVSB on 3 July 1989...
777:
Minutes of the First Meeting on 4 April 1989 at the Department of Health
1702: 1466: 1445: 1325:"Professor Bloom and Cardiff Haemophilia Centre - Inquiry Presentation" 834:
Follow Up Submission by the Scottish National Blood Transfusion Service
413: 775:
Advisory Committee on the Virological Safety of Blood (4 April 1989).
1487:(Report). Department of Health. April 2000. p. 6. Archived from 449: 1077:"Fifth Meeting of Advisory Committee on Virological Safety of Blood" 329: 1385:"ACVSB Minutes - Parvovirus B19 Contamination of Factor Products" 653:"Advisory Committee on the Virological Safety of Blood - Members" 1504:...although volumes 14-17 were destroyed, volumes 1-3 survive... 55: 686:"Dr Jeremy Metters (scheduled to give evidence 14th July 1998)" 242: 1667:"Bereaved families fear blood scandal cover-up by officials" 586:"Bereaved families fear blood scandal cover‑up by officials" 1742:
Defunct departments of the Government of the United Kingdom
1420:(Report). House of Commons Library. p. 22. SN/SC/5698 760:
The task of the Advisory Committee was to devise policy...
1637:"Shred of Evidence; Fury at HIV blood scandal 'cover-up'" 1295:"Minutes of the Eleventh Meeting Held on 29 October 1991" 374:, hepatitis A, virally inactivated fresh frozen plasma. 619:
Advisory Committee on the Virological Safety of Blood.
1546:
Carrell, Severin; Perraudin, Frances (25 March 2015).
1205:"Minutes of the 9th Meeting held on 25 February 1991" 1173:"Minutes of the 8th Meeting held on 21 November 1990" 117:
Advisory Committee on the Virological Safety of Blood
22:
Advisory Committee on the Virological Safety of Blood
810:. Preliminary Report (Report). Penrose Inquiry. 2010 1240:(Report). BSE Inquiry. YB 91/1.2/2.7 (BSE21/1 0074) 952:"Minutes of the Second Meeting Held on 22 May 1989" 101: 85: 77: 69: 61: 50: 42: 34: 26: 1109:"Minutes of the 6th meeting held on 24 April 1990" 981:"A & Ors v National Blood Authority & Ors" 38:Microbiological Safety of Blood and Tissues (MSBT) 1527:. Infected Blood Inquiry. p. 26. WITN4505389 1365:. Penrose Inquiry. 21 February 1992. SNB.001.9204 1214:. Penrose Inquiry. 25 February 1991. SNB.001.8934 1182:. Penrose Inquiry. 21 November 1990. SNB.001.1777 1304:. Penrose Inquiry. 29 October 1991. SNB.001.9148 1086:. Penrose Inquiry. 17 January 1990. SNF.001.1491 1051:. Penrose Inquiry. 30 October 1989. SNF.001.1383 719:A & Ors v National Blood Authority & Ors 537:A & Ors v National Blood Authority & Ors 462:Contaminated blood scandal in the United Kingdom 1518:"Third Written Statement of Charles Lister OBE" 1118:. Penrose Inquiry. 24 April 1990. SNB.001.9761 735: 733: 770: 768: 16:Defunct UK advisory committee on blood safety 8: 1665:Burgess, Kaya; Halle, Martyn (13 May 2019). 1272:. Penrose Inquiry. 21 May 1991. SNB.001.9107 1150:. Penrose Inquiry. 2 July 1990. SNF.001.1706 1019:. Penrose Inquiry. 3 July 1989. SNB.001.9513 961:. Penrose Inquiry. 22 May 1989. SNB.001.9416 584:Burgess, Kaya; Halle, Martyn (13 May 2019). 21: 1010:"Minutes of the 3rd Meeting of 3 July 1989" 862:Written Statement of Dr Gail Miflin (NHSBT) 836:(Report). Scottish Parliament. SP Paper 398 1470:. House of Commons. col. 1742W–1743W. 1350: 1348: 1289: 1287: 1257: 1255: 1199: 1197: 1167: 1165: 1135: 1133: 1103: 1101: 1071: 1069: 1042:"Department of Health and Social Security" 1036: 1034: 802: 800: 557:(Report). Penrose Inquiry. 2010. para 9.34 20: 1706:. House of Commons. col. 571W–573W. 856: 854: 679: 677: 614: 612: 531: 529: 647: 645: 579: 577: 575: 187: 782:(Report). Penrose Inquiry. SNF.001.1219 494: 492: 488: 467:Contaminated haemophilia blood products 436:A and Others v National Blood Authority 1462:"Destroyed Documents (Blood Products)" 1449:. House of Lords. col. WA26–WA27. 328:(ME) and blood transfusion, CJD agent/ 1482:Hepatitis C Litigation - Final Report 510:. Infected Blood Inquiry. WITN3530007 448:, the ACVSB recommended the use of a 109:Dr J Metters (chair from August 1989) 7: 1732:Blood donation in the United Kingdom 1330:. Infected Blood Inquiry. p. 79 1248:– via nationalarchives.gov.uk. 877:The ACVSB first met on 4 April 1989. 119:, often abbreviated to ACVSB, was a 1441:"NHS: Contaminated Blood Products" 1413:Dr Gavin Colthart (13 July 2011). 501:"Written Statement of Marc Turner" 14: 1635:Selby, Alan (27 September 2020). 1323:Ms Richards (24 September 2020). 684:Metters, Jeremy (14 July 1998). 319:Hepatitis C: UKBTS pilot study, 1703:Parliamentary Debates (Hansard) 1516:Lister, Charles (19 May 2022). 1467:Parliamentary Debates (Hansard) 1446:Parliamentary Debates (Hansard) 1235:ACVSB paper: Prions & Blood 1233:Dr H Pickles (2 January 1991). 929:. Penrose Inquiry. SNF.017.2159 900:. Penrose Inquiry. SGH.003.1137 889:Tucker, G W (8 February 1993). 662:. Penrose Inquiry. SNB.001.9364 630:. Penrose Inquiry. SNB.001.9366 499:Turner, Marc (7 October 2021). 222:HTLV-I, Non A Non B hepatitis, 920:"A38112 Schedule of Questions" 1: 1502:– via Squarespace.com. 140:-screening of blood donors. 808:"9 - Hepatitis 1986 to date" 243:Human Immunodeficiency Virus 127:to devise policy and advise 123:formed in March 1989 in the 1671:The Times (London, England) 1525:infectedbloodinquiry.org.uk 508:infectedbloodinquiry.org.uk 1758: 472:HIV Haemophilia Litigation 446:HIV Haemophilia Litigation 247:human coagulation proteins 1737:History of blood donation 1581:www.penroseinquiry.org.uk 832:Health Committee (2001). 174:Creutzfeldt–Jakob disease 164:, Non A Non B Hepatitis, 326:chronic fatigue syndrome 1698:"Blood: Contamination" 423:Hepatitis C Litigation 189:Meetings of the ACVSB 172:and the prion disease 107:Dr E L Harris (chair); 1363:penroseinquiry.org.uk 1302:penroseinquiry.org.uk 1270:penroseinquiry.org.uk 1212:penroseinquiry.org.uk 1180:penroseinquiry.org.uk 1148:penroseinquiry.org.uk 1116:penroseinquiry.org.uk 1084:penroseinquiry.org.uk 1049:penroseinquiry.org.uk 1017:penroseinquiry.org.uk 959:penroseinquiry.org.uk 927:penroseinquiry.org.uk 898:penroseinquiry.org.uk 748:penroseinquiry.org.uk 695:. BSE Inquiry. No 116 660:penroseinquiry.org.uk 628:penroseinquiry.org.uk 54:Dr H. H. Gunson, and 1643:. London. p. 28 1391:. TaintedBlood. 2006 621:"Terms of Reference" 407:Destruction of files 224:Human Growth Hormone 133:Department of Health 400:in blood products. 190: 23: 1681:– via Gale. 1494:on 29 January 2022 555:Preliminary Report 390:Fourteenth meeting 379:Thirteenth meeting 188: 1389:taintedblood.info 693:bseinquiry.gov.uk 404: 403: 393:29 September 1992 332:in blood donors. 239:gamma irradiation 200:Topics discussed 113: 112: 1749: 1711: 1710: 1693: 1687: 1686: 1680: 1678: 1662: 1656: 1655: 1650: 1648: 1632: 1626: 1625: 1619: 1617: 1602: 1596: 1595: 1589: 1587: 1573: 1567: 1566: 1560: 1558: 1543: 1537: 1536: 1534: 1532: 1522: 1513: 1507: 1506: 1501: 1499: 1493: 1486: 1478: 1472: 1471: 1457: 1451: 1450: 1436: 1430: 1429: 1427: 1425: 1419: 1410: 1404: 1403: 1398: 1396: 1381: 1375: 1374: 1372: 1370: 1360: 1352: 1343: 1342: 1337: 1335: 1329: 1320: 1314: 1313: 1311: 1309: 1299: 1291: 1282: 1281: 1279: 1277: 1267: 1259: 1250: 1249: 1247: 1245: 1239: 1230: 1224: 1223: 1221: 1219: 1209: 1201: 1192: 1191: 1189: 1187: 1177: 1169: 1160: 1159: 1157: 1155: 1145: 1137: 1128: 1127: 1125: 1123: 1113: 1105: 1096: 1095: 1093: 1091: 1081: 1073: 1064: 1063: 1058: 1056: 1046: 1038: 1029: 1028: 1026: 1024: 1014: 1006: 1000: 999: 994: 992: 977: 971: 970: 968: 966: 956: 948: 942: 941: 936: 934: 924: 916: 910: 909: 907: 905: 895: 886: 880: 879: 874: 872: 866: 858: 849: 848: 843: 841: 829: 823: 822: 817: 815: 804: 795: 794: 789: 787: 781: 772: 763: 762: 757: 755: 745: 737: 728: 722: 714: 708: 707: 702: 700: 690: 681: 672: 671: 669: 667: 657: 649: 640: 639: 637: 635: 625: 616: 607: 606: 601: 599: 581: 570: 569: 564: 562: 551: 545: 539: 533: 524: 523: 517: 515: 505: 496: 363:21 February 1992 348:Eleventh meeting 316:25 February 1991 305:21 November 1990 191: 94: 24: 1757: 1756: 1752: 1751: 1750: 1748: 1747: 1746: 1717: 1716: 1715: 1714: 1695: 1694: 1690: 1676: 1674: 1664: 1663: 1659: 1646: 1644: 1634: 1633: 1629: 1615: 1613: 1604: 1603: 1599: 1585: 1583: 1575: 1574: 1570: 1556: 1554: 1545: 1544: 1540: 1530: 1528: 1520: 1515: 1514: 1510: 1497: 1495: 1491: 1484: 1480: 1479: 1475: 1459: 1458: 1454: 1438: 1437: 1433: 1423: 1421: 1417: 1412: 1411: 1407: 1394: 1392: 1383: 1382: 1378: 1368: 1366: 1358: 1354: 1353: 1346: 1333: 1331: 1327: 1322: 1321: 1317: 1307: 1305: 1297: 1293: 1292: 1285: 1275: 1273: 1265: 1261: 1260: 1253: 1243: 1241: 1237: 1232: 1231: 1227: 1217: 1215: 1207: 1203: 1202: 1195: 1185: 1183: 1175: 1171: 1170: 1163: 1153: 1151: 1143: 1139: 1138: 1131: 1121: 1119: 1111: 1107: 1106: 1099: 1089: 1087: 1079: 1075: 1074: 1067: 1054: 1052: 1044: 1040: 1039: 1032: 1022: 1020: 1012: 1008: 1007: 1003: 990: 988: 987:. 26 March 2001 979: 978: 974: 964: 962: 954: 950: 949: 945: 932: 930: 922: 918: 917: 913: 903: 901: 893: 888: 887: 883: 870: 868: 864: 860: 859: 852: 839: 837: 831: 830: 826: 813: 811: 806: 805: 798: 785: 783: 779: 774: 773: 766: 753: 751: 743: 739: 738: 731: 716: 715: 711: 698: 696: 688: 683: 682: 675: 665: 663: 655: 651: 650: 643: 633: 631: 623: 618: 617: 610: 597: 595: 583: 582: 573: 560: 558: 553: 552: 548: 542: QB 446 535: 534: 527: 513: 511: 503: 498: 497: 490: 485: 477:Penrose Inquiry 458: 431: 409: 360:Twelfth meeting 351:29 October 1991 287:Seventh meeting 268:17 January 1990 257:6 November 1989 182: 108: 104: 97: 92: 17: 12: 11: 5: 1755: 1753: 1745: 1744: 1739: 1734: 1729: 1719: 1718: 1713: 1712: 1688: 1657: 1627: 1610:www.bailii.org 1597: 1568: 1538: 1508: 1473: 1452: 1431: 1405: 1376: 1344: 1315: 1283: 1251: 1225: 1193: 1161: 1129: 1097: 1065: 1030: 1001: 972: 943: 911: 881: 850: 824: 796: 764: 750:. 4 April 1989 729: 709: 673: 641: 608: 571: 546: 525: 487: 486: 484: 481: 480: 479: 474: 469: 464: 457: 454: 430: 427: 421:list from the 408: 405: 402: 401: 398:parvovirus B19 394: 391: 387: 386: 383: 380: 376: 375: 364: 361: 357: 356: 352: 349: 345: 344: 341: 338: 334: 333: 317: 314: 310: 309: 306: 303: 302:Eighth meeting 299: 298: 291: 288: 284: 283: 280: 277: 273: 272: 269: 266: 262: 261: 258: 255: 254:Fourth meeting 251: 250: 235: 232: 228: 227: 220: 217: 216:Second meeting 213: 212: 209: 206: 202: 201: 198: 195: 181: 178: 146:blood products 125:United Kingdom 111: 110: 105: 102: 99: 98: 96: 95: 93:United Kingdom 89: 87: 83: 82: 79: 75: 74: 71: 67: 66: 63: 59: 58: 52: 48: 47: 44: 40: 39: 36: 32: 31: 28: 15: 13: 10: 9: 6: 4: 3: 2: 1754: 1743: 1740: 1738: 1735: 1733: 1730: 1728: 1725: 1724: 1722: 1709: 1705: 1704: 1699: 1692: 1689: 1685: 1672: 1668: 1661: 1658: 1654: 1642: 1638: 1631: 1628: 1624: 1611: 1607: 1601: 1598: 1594: 1582: 1578: 1572: 1569: 1565: 1553: 1549: 1542: 1539: 1526: 1519: 1512: 1509: 1505: 1490: 1483: 1477: 1474: 1469: 1468: 1463: 1456: 1453: 1448: 1447: 1442: 1435: 1432: 1416: 1409: 1406: 1402: 1390: 1386: 1380: 1377: 1364: 1357: 1351: 1349: 1345: 1341: 1326: 1319: 1316: 1303: 1296: 1290: 1288: 1284: 1271: 1264: 1258: 1256: 1252: 1236: 1229: 1226: 1213: 1206: 1200: 1198: 1194: 1181: 1174: 1168: 1166: 1162: 1149: 1142: 1136: 1134: 1130: 1117: 1110: 1104: 1102: 1098: 1085: 1078: 1072: 1070: 1066: 1062: 1050: 1043: 1037: 1035: 1031: 1018: 1011: 1005: 1002: 998: 986: 982: 976: 973: 960: 953: 947: 944: 940: 928: 921: 915: 912: 899: 892: 885: 882: 878: 863: 857: 855: 851: 847: 835: 828: 825: 821: 809: 803: 801: 797: 793: 778: 771: 769: 765: 761: 749: 742: 736: 734: 730: 726: 721: 720: 713: 710: 706: 694: 687: 680: 678: 674: 661: 654: 648: 646: 642: 629: 622: 615: 613: 609: 605: 593: 592: 587: 580: 578: 576: 572: 568: 556: 550: 547: 543: 538: 532: 530: 526: 522: 509: 502: 495: 493: 489: 482: 478: 475: 473: 470: 468: 465: 463: 460: 459: 455: 453: 451: 447: 442: 441: 437: 429:Key decisions 428: 426: 424: 419: 415: 406: 399: 396:Detection of 395: 392: 389: 388: 384: 381: 378: 377: 373: 369: 365: 362: 359: 358: 353: 350: 347: 346: 342: 339: 337:Tenth meeting 336: 335: 331: 327: 322: 318: 315: 313:Ninth meeting 312: 311: 307: 304: 301: 300: 296: 292: 289: 286: 285: 281: 279:24 April 1990 278: 276:Sixth meeting 275: 274: 270: 267: 265:Fifth meeting 264: 263: 259: 256: 253: 252: 248: 244: 240: 236: 233: 231:Third meeting 230: 229: 225: 221: 218: 215: 214: 210: 207: 205:First meeting 204: 203: 199: 196: 193: 192: 186: 179: 177: 175: 171: 167: 163: 159: 155: 151: 147: 141: 139: 134: 130: 126: 122: 118: 106: 100: 91: 90: 88: 84: 80: 76: 72: 68: 65:February 1993 64: 60: 57: 53: 49: 45: 41: 37: 33: 29: 25: 19: 1707: 1701: 1691: 1682: 1675:. Retrieved 1670: 1660: 1652: 1645:. Retrieved 1640: 1630: 1621: 1614:. Retrieved 1609: 1600: 1591: 1584:. Retrieved 1580: 1571: 1562: 1555:. Retrieved 1552:the Guardian 1551: 1541: 1529:. Retrieved 1524: 1511: 1503: 1496:. Retrieved 1489:the original 1476: 1465: 1455: 1444: 1434: 1422:. Retrieved 1408: 1400: 1393:. Retrieved 1388: 1379: 1367:. Retrieved 1362: 1339: 1332:. Retrieved 1318: 1306:. Retrieved 1301: 1274:. Retrieved 1269: 1242:. Retrieved 1228: 1216:. Retrieved 1211: 1184:. Retrieved 1179: 1152:. Retrieved 1147: 1120:. Retrieved 1115: 1088:. Retrieved 1083: 1060: 1053:. Retrieved 1048: 1021:. Retrieved 1016: 1004: 996: 989:. Retrieved 985:casemine.com 984: 975: 963:. Retrieved 958: 946: 938: 931:. Retrieved 926: 914: 902:. Retrieved 897: 884: 876: 869:. Retrieved 845: 838:. Retrieved 827: 819: 812:. Retrieved 791: 784:. Retrieved 759: 752:. Retrieved 747: 717: 712: 704: 697:. Retrieved 692: 664:. Retrieved 659: 632:. Retrieved 627: 603: 596:. Retrieved 589: 566: 559:. Retrieved 549: 536: 519: 512:. Retrieved 507: 443: 439: 432: 410: 208:4 April 1989 183: 150:donor organs 142: 116: 114: 46:8 March 1989 27:Abbreviation 18: 1727:Hepatitis C 444:During the 382:2 July 1992 340:21 May 1991 290:2 July 1990 234:3 July 1989 219:22 May 1989 1721:Categories 1677:31 January 1647:31 January 1641:The People 1616:31 January 1586:31 January 1557:31 January 1498:29 January 1424:28 January 1395:27 January 1369:26 January 1334:31 January 1308:26 January 1276:26 January 1244:29 January 1218:26 January 1186:26 January 1154:26 January 1122:26 January 1090:25 January 1055:25 January 1023:26 January 991:25 January 965:26 January 933:25 January 904:26 January 871:23 January 840:23 January 814:22 January 786:23 January 754:23 January 699:23 January 666:23 January 634:23 January 598:24 January 561:23 January 514:23 January 483:References 170:parvovirus 103:Key people 591:The Times 418:The Times 129:ministers 121:committee 43:Formation 35:Successor 1684:viruses. 1564:start... 594:. London 456:See also 372:Yersinia 180:Meetings 131:and the 86:Location 73:Advisory 1593:1991... 1531:29 June 414:Hansard 241:on the 194:Meeting 176:(CJD). 62:Defunct 51:Founder 1612:. 2001 723:, 540:, 450:waiver 330:prions 295:plasma 162:HTLV-I 1521:(PDF) 1492:(PDF) 1485:(PDF) 1418:(PDF) 1359:(PDF) 1328:(PDF) 1298:(PDF) 1266:(PDF) 1238:(PDF) 1208:(PDF) 1176:(PDF) 1144:(PDF) 1112:(PDF) 1080:(PDF) 1045:(PDF) 1013:(PDF) 955:(PDF) 923:(PDF) 894:(PDF) 865:(PDF) 780:(PDF) 744:(PDF) 689:(PDF) 656:(PDF) 624:(PDF) 504:(PDF) 321:NIBSC 78:Focus 30:ACVSB 1679:2022 1673:: 21 1649:2022 1618:2022 1588:2022 1559:2022 1533:2022 1500:2022 1426:2022 1397:2022 1371:2022 1336:2022 1310:2022 1278:2022 1246:2022 1220:2022 1188:2022 1156:2022 1124:2022 1092:2022 1057:2022 1025:2022 993:2022 967:2022 935:2022 906:2022 873:2022 842:2022 816:2022 788:2022 756:2022 701:2022 668:2022 636:2022 600:2022 563:2022 516:2022 368:PHLS 245:and 197:Date 158:HIV2 156:and 154:HIV1 148:and 115:The 70:Type 56:DHSS 725:446 166:CMV 138:HCV 1723:: 1700:. 1669:. 1651:. 1639:. 1620:. 1608:. 1590:. 1579:. 1561:. 1550:. 1523:. 1464:. 1443:. 1399:. 1387:. 1361:. 1347:^ 1338:. 1300:. 1286:^ 1268:. 1254:^ 1210:. 1196:^ 1178:. 1164:^ 1146:. 1132:^ 1114:. 1100:^ 1082:. 1068:^ 1059:. 1047:. 1033:^ 1015:. 995:. 983:. 957:. 937:. 925:. 896:. 875:. 853:^ 844:. 818:. 799:^ 790:. 767:^ 758:. 746:. 732:^ 703:. 691:. 676:^ 658:. 644:^ 626:. 611:^ 602:. 588:. 574:^ 565:. 528:^ 518:. 506:. 491:^ 297:. 249:. 168:, 160:, 1535:. 1428:. 1373:. 1312:. 1280:. 1222:. 1190:. 1158:. 1126:. 1094:. 1027:. 969:. 908:. 670:. 638:. 440:.

Index

DHSS
committee
United Kingdom
ministers
Department of Health
HCV
blood products
donor organs
HIV1
HIV2
HTLV-I
CMV
parvovirus
Creutzfeldt–Jakob disease
Human Growth Hormone
gamma irradiation
Human Immunodeficiency Virus
human coagulation proteins
plasma
NIBSC
chronic fatigue syndrome
prions
PHLS
Yersinia
parvovirus B19
Hansard
The Times
Hepatitis C Litigation
A and Others v National Blood Authority
HIV Haemophilia Litigation

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑